Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer incidence in Egypt: results of the National Population-Based Cancer Registry Program. J Cancer Epidemiol. 2014;2014:437971.

Article  PubMed  PubMed Central  Google Scholar 

WORLD HEALTH RANKINGS; Lung cancer in Egypt – World Life Expectancy,2022; https://www.worldlifeexpectancy.com› Egypt-lung-cancers

Mattox AK, Bettegowda C, Zhou S, Papadopoulos N, Kinzler KW, Vogelstein B. Applications of liquid biopsies for cancer. Sci Transl Med. 2019;11:eaay1984.

Article  PubMed  Google Scholar 

Xie F, Li P, Gong J, Tan H, Ma J. Urinary cell-free DNA as a prognostic marker for KRAS-positive advanced-stage NSCLC. Clin Transl Oncol. 2018;20:591–8.

Article  CAS  PubMed  Google Scholar 

Von Felden J, Garcia-Lezana T, Schulze K, Losic B, Villanueva A. Liquid biopsy in the clinical management of hepatocellular carcinoma. Gut. 2020;69:2025–34.

Article  Google Scholar 

Roy D, Tiirikainen M. Diagnostic power of DNA methylation classifiers for early detection of cancer. Trends Cancer. 2020;6:78–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou B, Xu K, Zheng X, Chen T, Wang J, Song Y, Shao Y, Zheng S. Application of exosomes as liquid biopsy in clinical diagnosis. Signal Transduct Target Ther. 2020;5:1–14.

CAS  Google Scholar 

Mattox AK, Bettegowda C, Zhou S, Papadopoulos N, Kinzler KW, Vogelstein B. Applications of liquid biopsies for cancer. Sci Transl Med. 2019;11:eaay1984.

Article  PubMed  Google Scholar 

Gao W, Huang T, Yuan H, Yang J, Jin Q, Jia C, Mao G, Zhao J. Highly sensitive detection and mutational analysis of lung cancer circulating tumor cells using integrated combined immunomagnetic beads with a droplet digital PCR chip. Talanta. 2018;185:229–36.

Article  CAS  PubMed  Google Scholar 

Guibert N, Delaunay M, Lusque A, Boubekeur N, Rouquette I, Clermont E, Mourlanette J, Gouin S, Dormoy I, Favre G. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab. Lung Cancer. 2018;120:108–12.

Article  PubMed  Google Scholar 

Akamatsu H, Koh Y, Okamoto I, Fujimoto D, Bessho A, Azuma K, Morita S, Yamamoto N, Nakagawa K. Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients treated with afatinib (West Japan Oncology Group 8114LTR study). Lung Cancer. 2019;131:128–33.

Article  PubMed  Google Scholar 

Okajima W, Komatsu S, Ichikawa D, Miyamae M, Kawaguchi T, Hirajima S, Ohashi T, Imamura T, Kiuchi J, Arita T. Circulating microRNA profiles in plasma: identification of miR-224 as a novel diagnostic biomarker in hepatocellular carcinoma independent of hepatic function. Oncotarget. 2016;7:53820–36.

Article  PubMed  PubMed Central  Google Scholar 

Zedan AH, Hansen TF, Assenholt J, Madsen JS, Osther PJS. Circulating miRNAs in localized/locally advanced prostate cancer patients after radical prostatectomy and radiotherapy. Prostate. 2018;79:425–32.

Article  PubMed  PubMed Central  Google Scholar 

Avogbe PH, Manel A, Vian E, Durand G, Forey N, Voegele C, Zvereva M, Hosen I, Meziani S, De Tilly B. Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer. EBioMedicine. 2019;44:431–8.

Article  PubMed  PubMed Central  Google Scholar 

Song T, Mao F, Shi L, Xu X, Wu Z, Zhou J, Xiao M. Urinary measurement of circulating tumor DNA for treatment monitoring and prognosis of metastatic colorectal cancer patients. Clin Chem Lab Med. 2018;57:268–75.

Article  PubMed  Google Scholar 

Garinet S, Laurent-Puig P, Blons H, Oudart J. Review current and futuremolecular testing in NSCLC, what can we expect from new sequencing technologies? J Clin Med. 2018;7:144.

Article  PubMed  PubMed Central  Google Scholar 

Umetani N, Giuliano AE, Hiramatsu SH, Amersi F, Nakagawa T, Martino S, Hoon DS. Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol. 2006;24(26):4270–6.

Article  CAS  PubMed  Google Scholar 

Umetani N, Kim J, Hiramatsu S, Reber HA, Hines OJ, Bilchik AJ, Hoon DS. Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin Chem. 2006;52(6):1062–9.

Article  CAS  PubMed  Google Scholar 

Oliveira IBD. Hirata RDC;Circulating cell-free DNA as a biomarker in the diagnosis and prognosis of colorectal cancer. Br J Pharmaceutical Sciences. 2018;54:e17368.

Google Scholar 

Wang X, Shi XQ, Zeng PW, Mo FM, Chen ZH. Circulating cell free DNA as the diagnostic marker for colorectal cancer: a systematic review and meta-analysis. Oncotarget. 2018;9:24514–24.

Article  PubMed  PubMed Central  Google Scholar 

El-Shazly SF, Eid MA, El-Sourogy HA, Attia GF, Ezzat SA. Evaluation of serum DNA integrity as a screening and prognostic tool in patients with hepatitis C virus-related hepatocellular carcinoma. Int J Biol Markers. 2010;25(2):79–86.

Article  CAS  PubMed  Google Scholar 

Hashad D, Sorour A, Ghazal A, Talaat I. Free circulating tumor DNA as a diagnostic marker for breast cancer. J Clin Lab Anal. 2012;26(6):467–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kamel AM, Teama S, Fawzy A, El Deftar M. Plasma DNA integrity index as a potential molecular diagnostic marker for breast cancer. Tumour Biol. 2016;37:7565–72.

Article  CAS  PubMed  Google Scholar 

Ilie M, Hofman V, Long E, Bordone O, Selva E, Washetine K, Marquette CH, Hofman P. Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients What is the best blood substrate for personalized medicine? Ann Transl Med. 2014;2(11):107.

PubMed  PubMed Central  Google Scholar 

Zhang Y, Zheng H, Zhan Y, Long M, Liu S, Lu J, Zang H, Fan S. Detection and application of circulating tumor cell and circulating tumor DNA in the non-small cell lung cancer. Am J Cancer Res. 2018;8(12):2377–86.

CAS  PubMed  PubMed Central  Google Scholar 

Chudasama DY, Aladag Z, Felicien MI, Hall M, Beeson J, Asadi N, Anikin VB. Prognostic value of the DNA integrity index in patients with malignant lung tumors. Oncotarget. 2018;9(30):21281–8.

Article  PubMed  PubMed Central  Google Scholar 

Francaviglia I, Magliacane G, Lazzari C, Grassini G, Brunetto E, Cin ED, Girlando S, Medicina D, Smart CE, Bulotta A. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients. Lung Cancer. 2019;134:225–32.

Article  PubMed  Google Scholar 

Szpechcinski A, Dancewicz M, Kopinski P, Kowalewski J, Chorostowska-Wynimko J. Real-time PCR quantification of plasma DNA in non-small cell lung cancer patients and healthy controls. Eur J Med Res. 2009;14(4):237–40.

Article  PubMed  PubMed Central  Google Scholar 

van der Drift MA, Hol BE, Klaassen CH, Prinsen CF, van Aarssen YA, Donders R, van der Stappen JW, Dekhuijzen PN, van der Heijden HF, Thunnissen FB. Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer. Lung Cancer. 2010;68(2):283–7.

Article  PubMed  Google Scholar 

Hao TB, Shi W, Shen XJ, Qi J, Wu XH, Wu Y, Tang YY, Ju SQ. Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer. Br J Cancer. 2014;14 111(8):1482–9.

Article  Google Scholar 

Szpechcinski A, Chorostowska-Wynimko J, Struniawski R, Kupis W, Rudzinski P, Langfort R, Puscinska E, Bielen P, Sliwinski P, Orlowski T. Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease. Br J Cancer. 2015;113(3):476–83.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chudasama DY, Aladag Z, Felicien MI, Hall M, Beeson J, Asadi N, Gidron Y, Karteris E, Anikin VB. Prognostic value of the DNA integrity index in patients with malignant lung tumors. Oncotarget. 2018;9(30):21281–8.

Article  PubMed  PubMed Central